Dr. Chul Kim, MD, MPH

Dr. Chul Kim, MD, MPH

Dr. Chul Kim, MD, MPH

Languages: English, Korean
Fax: (202) 444-0770

Contact this Provider:

  • Hematology Oncology
  • Medical Oncology
Conditions I Treat
  • lung cancer
  • mesothelioma
  • thymus cancer
Procedures I Perform
  • biological targeted therapy
  • cancer chemotherapy
  • cancer immunotherapy
  • chemoradiation
About the Provider

Dr. Chul Kim is an Assistant Professor at Georgetown University focusing on thoracic oncology. He strives to bring novel cancer immunotherapies and targeted therapies to the clinic and devise clinical trials to develop personalized cancer treatments.

Dr. Kim graduated Summa Cum Laude from Sungkyunkwan University School of Medicine in Seoul, South Korea and obtained his Master’s degree in Public Health from Harvard School of Public Health. He received training in internal medicine at the University of Minnesota. He was a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH). He received a Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) in 2018.

He has published more than 40 articles in peer-reviewed journals such as Lancet Oncology, JAMA Oncology, Journal of Thoracic OncologyJournal for ImmunoTherapy of Cancer, and Clinical Cancer Research. He has served as a reviewer for several journals including Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology. He is a member of American Society of Clinical Oncology and International Association for the Study of Lung Cancer.

His goal as an oncologist is to provide the best possible treatment for his patients.

  • Fellowship Program: National Cancer Institute (2017)
  • Residency Program: Univ. of Minnesota Hospital and Clinic (2014)
  • Medical School: Sungkyunkwan University School of Medicine (2007)
  • Board Certification: American Board of Internal Medicine, Medical Oncology
  • Board Certification: American Board of Internal Medicine, Hematology
  • Board Certification: American Board of Internal Medicine, Internal Medicine

Original papers in refereed journals 

1.         Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578). Epub 2021/01/29. doi: 10.1126/scitranslmed.abc7488. PubMed PMID: 33504652.

2.         Peravali M, Joshi I, Ahn J, Kim C. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep. 2021;2(3):100141. Epub 2021/01/14. doi: 10.1016/j.jtocrr.2020.100141. PubMed PMID: 33437971; PMCID: PMC7790456.

3.         McGunigal M, Margolis M, Forsthoefel M, Singh T, Amarell K, Deblois D, Campbell L, Kim C, Liu S, Bergquist PJ. Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta Oncologica. 2021:1-4.

4.         Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports. 2021;2(4):100149.

5.         Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2021;16(3):483-5. Epub 2020/11/29. doi: 10.1016/j.jtho.2020.11.003. PubMed PMID: 33248322.

6.         Estrada-Bernal A, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV, Kim C, Liu SV, Doebele RC. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021;27(5):1463-75. Epub 2020/12/24. doi: 10.1158/1078-0432.CCR-20-3555. PubMed PMID: 33355298; PMCID: PMC7926264.

7.         Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Journal for immunotherapy of cancer. 2021;9(2).

8.         Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168-75. Epub 2020/05/07. doi: 10.1016/j.ejca.2020.03.015. PubMed PMID: 32375103.

9.         Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. J Cancer Surviv. 2020;14(1):53-8. Epub 2019/11/07. doi: 10.1007/s11764-019-00826-1. PubMed PMID: 31686365.

10.       Roper N, Brown A-L, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, Meskini RE, Ohler ZW, Maity TK, Venugopala A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Pachenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine. 2020;1(1).

11.       Peravali M, Wang H, Kim C, Veytsman I. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Curr Oncol Rep. 2020;22(12):119. Epub 2020/09/19. doi: 10.1007/s11912-020-00981-0. PubMed PMID: 32945977.

12.       Li N, Guha U, Kim C, Ye L, Cheng J, Li F, Chia D, Wei F, Wong DT. Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. Frontiers in oncology. 2020;10:1240.

13.       Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2). Epub 2020/07/04. doi: 10.1136/jitc-2020-000980. PubMed PMID: 32616557; PMCID: PMC7333915.

14.       Kareff SA, Lischalk JW, Krochmal R, Kim C. Abscopal effect in pulmonary carcinoid tumor following ablative stereotactic body radiation therapy: a case report. J Med Case Rep. 2020;14(1):177. Epub 2020/10/05. doi: 10.1186/s13256-020-02512-8. PubMed PMID: 33010806; PMCID: PMC7532944.

15.       Farid S, Latif H, Nilubol C, Kim C. Immune Checkpoint Inhibitor-induced Fanconi Syndrome. Cureus. 2020;12(4):e7686. doi: 10.7759/cureus.7686.

16.       Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353. Epub 2019/12/19. doi: 10.1186/s40425-019-0771-1. PubMed PMID: 31847881; PMCID: PMC6918622.

17.       Desai S, Kim C, Veytsman I. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give? Curr Oncol Rep. 2019;21(9):84. Epub 2019/08/15. doi: 10.1007/s11912-019-0835-x. PubMed PMID: 31410582.

18.       Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019;5(7):1049-54. Epub 2019/02/08. doi: 10.1001/jamaoncol.2018.6737. PubMed PMID: 30730549.

19.       Al-Shbool G, Latif H, Farid S, Wang S, Ahn J, Giaccone G, Kim C. Publication Rate and Characteristics of Lung Cancer Clinical Trials. JAMA Netw Open. 2019;2(11):e1914531. Epub 2019/11/07. doi: 10.1001/jamanetworkopen.2019.14531. PubMed PMID: 31693119; PMCID: PMC6865260.

20.       Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347-55. Epub 2018/02/06. doi: 10.1016/S1470-2045(18)30062-7. PubMed PMID: 29395863.

21.       Valle L, Thomas J, Kim C, Szabo E, Brown GT, Citrin D, Rajan A. Hepatoid adenocarcinoma of the lung metastasizing to the tonsil. Mol Clin Oncol. 2017;6(5):705-7. Epub 2017/05/23. doi: 10.3892/mco.2017.1215. PubMed PMID: 28529745; PMCID: PMC5431682.

22.       Gharwan H, Kim C, Thomas A, Berman A, Kim SA, Biassou N, Steinberg SM, Rajan A. Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. Transl Lung Cancer Res. 2017;6(5):588-99. Epub 2017/11/09. doi: 10.21037/tlcr.2017.08.06. PubMed PMID: 29114474; PMCID: PMC5653528.

23.       Del Rivero J, Kim C, Eid M, Ahlman MA, Nieman LK, Rajan A. Thymic Hyperplasia after Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. J Thorac Oncol. 2017;12(4):e29-e32. Epub 2016/11/21. doi: 10.1016/j.jtho.2016.11.2215. PubMed PMID: 27865872.

24.       Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Dominguez E, Garcia-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS One. 2017;12(10):e0175484. Epub 2017/10/06. doi: 10.1371/journal.pone.0175484. PubMed PMID: 28981524; PMCID: PMC5628783.

25.       Kim C, Zhang X, Chan AT, Sesso HD, Rifai N, Stampfer MJ, Ma J. Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. Cancer Epidemiol. 2016;44:65-70. Epub 2016/08/10. doi: 10.1016/j.canep.2016.07.012. PubMed PMID: 27504605; PMCID: PMC5821121.

26.       Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016;5(6):720-6. Epub 2017/02/06. doi: 10.21037/tlcr.2016.11.06. PubMed PMID: 28149767; PMCID: PMC5233874.

27.       Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016. Epub 2016/05/30. doi: 10.1016/j.mayocp.2016.02.012. PubMed PMID: 27236424; PMCID: PMC5104665.

28.       Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015;175(8):1389-98. Epub 2015/06/23. doi: 10.1001/jamainternmed.2015.2829. PubMed PMID: 26098871.

29.       Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015;175(12):1992-4. Epub 2015/10/27. doi: 10.1001/jamainternmed.2015.5868. PubMed PMID: 26502403.

30.       Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Res. 2015;35(1):301-9. Epub 2015/01/01. PubMed PMID: 25550564.

31.       Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015;25(1):75-9. Epub 2014/11/27. doi: 10.1097/CMR.0000000000000133. PubMed PMID: 25426645.

32.       Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27-32. Epub 2013/05/30. doi: 10.1161/HYPERTENSIONAHA.113.01453. PubMed PMID: 23716587; PMCID: PMC3729220.

33.       Paik KH, Lee MK, Jin DK, Kang HW, Lee KH, Kim AH, Kim C, Lee JE, Oh YJ, Kim S, Han SJ, Kwon EK, Choe YH. Marked suppression of ghrelin concentration by insulin in Prader-willi syndrome. J Korean Med Sci. 2007;22(2):177-82. Epub 2007/04/24. doi: 10.3346/jkms.2007.22.2.177. PubMed PMID: 17449920; PMCID: PMC2693578.


Reviews or editorials in refereed journals

1.         Jonna S, Reuss JE, Kim C, Liu SV. Oral Chemotherapy for Treatment of Lung Cancer. Frontiers in Oncology. 2020;10:793.

2.         Friedlaender A, Kim C, Addeo A. Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic. Frontiers in Oncology. 2020;10:862.

3.         Kim C, Liu S. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Oxford University Press; 2019.

4.         Kim C, Giaccone G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(6):348-9. Epub 2018/03/31. doi: 10.1038/s41571-018-0008-0. PubMed PMID: 29599475.

5.         Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27(1):17-30. Epub 2017/12/09. doi: 10.1080/13543784.2018.1415324. PubMed PMID: 29216787.

6.         Kim C, Giaccone G. The role of immune checkpoint blockade for treatment of thymic epithelial tumors—a delicate balance between efficacy and side effects2018.

7.         Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):179-93. Epub 2016/10/27. doi: 10.1016/j.jtho.2016.10.012. PubMed PMID: 27780780.

8.         Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother. 2016;12(9):2219-31. Epub 2016/05/03. doi: 10.1080/21645515.2016.1175694. PubMed PMID: 27135835; PMCID: PMC5027703.

9.         Kim C, Giaccone G. Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Ann Transl Med. 2016;4(23):466. Epub 2017/01/17. doi: 10.21037/atm.2016.11.48. PubMed PMID: 28090522; PMCID: PMC5220042.

In the News





    MedStar Health Providers participate with a wide range of health insurance products. We accept self-pay patients and the insurances plans listed below. This list is not comprehensive, it is updated periodically and is subject to change. If you do not see your health insurance plan or product listed, or if you have any questions regarding MedStar Health’s participation with your health plan, please contact your health plan to verify participation with our providers.

    Since the MedStar Health providers span the District of Columbia, Maryland and Virginia regions, our participation with DC, Maryland and Virginia Medical Assistance programs varies by provider group. Please contact your MedStar Physician’s Office to assist with verifying Medical Assistance participation. If you are enrolled in a Medicaid Managed Care Organization, please contact your Medicaid health plan to verify participation.

Practice Locations
  • 110 Irving Street Northwest
    Floor 2
    Washington, DC 20010
    View Map

  • 3800 Reservoir Road Northwest
    Washington, DC 20007
    View Map

    Phone: (202) 444-2223
    Fax: (202) 444-0770

Member of Medical Staff
  • MedStar Washington Hospital Center
  • MedStar Georgetown University Hospital